|
| Press Releases |
|
 |
|
| Friday, October 18, 2024 |
|
|
Everest Medicines' Stock Price Rises by 20% as Profit Potential Drives Valuation Recovery |
| Everest Medicines (1952.HK) closed today with a 20.46% increase, hitting a high of HKD 28.6. The company's stock price has been steadily rising since the release of its interim results, with today's trading volume reaching HKD 291 million. Market updates show that BOCOM International released a report assigning an 'outperform' rating to the Chinese pharmaceutical sector, with Everest Medicines being one of the key recommended stocks. more info >> |
|
| Wednesday, October 2, 2024 |
|
|
NEFECON Included in 2024 KDIGO Clinical Practice Guidelines |
| Recently, Everest Medicines has announced another positive development. The company's lead product, NEFECON, as the only in-disease IgA nephropathy (IgAN) treatment, has been included in the "KDIGO 2024 Clinical Practice Guideline for the Management Of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) (Public Review Draft)" (hereinafter referred to as the "New Guidelines (Draft)"), recommending treatment with a 9-month course of NEFECON for patients who are at risk of progressive kidney function loss with IgAN (2B). more info >> |
|
| Thursday, August 22, 2024 |
|
|
Everest Medicines Announces the Initiation of an Investigator-Initiated Clinical Trial (IIT) |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced the launch of an Investigator-Initiated Clinical Trial (IIT) for a personalized mRNA cancer vaccine, EVM16, under the study EVM16CX01, at the Peking University Cancer Hospital and Fudan University's Cancer Hospital. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Theinvestmedia.com Offers Exclusive Brokerage Account Opening Offers and In-Depth Tutorials, Empowering Investors with Precise Decision-Making
Jul 26, 2025 08:00 HKT/SGT
|
|
|
maxWin Receives Honesty Award 2025, Setting New Standards for Integrity in Online Gaming 
Jul 25, 2025 19:00 HKT/SGT
|
|
|
OMS Energy Recorded Significant Profits Growth in 2025FY, Roth Capital Rating it "Buy" with a Potential 40% Upside TP
Jul 25, 2025 17:18 HKT/SGT
|
|
|
CWE held 'Lancang Mekong Green Course' Open Day to celebrate the 10th anniversary of the Nam Ngiep 2 Hydropower Station
Jul 25, 2025 16:25 HKT/SGT
|
|
|
Olympus Enters Strategic Partnership to Develop Endoluminal Gastrointestinal Robotics
Jul 25, 2025 16:00 JST
|
|
|
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
Jul 25, 2025 13:31 JST
|
|
|
Ultraman Omega joins the battlefield alongside beloved Ultraman Arc in Tsuburaya Production's new Starter Deck 03 'Ω to the Future' and Booster Pack 4 'Gleam of Eternal Hope'
Jul 25, 2025 12:25 HKT/SGT
|
|
|
Multi-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China
Jul 25, 2025 10:52 HKT/SGT
|
|
|
Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million
Jul 25, 2025 10:01 HKT/SGT
|
|
|
International Land Alliance Announces Tiny Home Offerings at Cabo Oasis Development
Jul 24, 2025 22:04 HKT/SGT
|
|
|
HKTDC Research Report: Exploring Opportunities in Hong Kong's Proprietary Chinese Medicine Industry
Jul 24, 2025 17:43 HKT/SGT
|
|
|
ONERHT Foundation's 8th GAIL Forum held on 22 July 2025, Champions Green Leadership Across ASEAN
Jul 24, 2025 14:00 HKT/SGT
|
|
|
Quantum Solutions Announces Strategic Bitcoin Treasury Initiative
Jul 24, 2025 13:51 HKT/SGT
|
|
|
Fujitsu and Nagoya University develop simulation tech to combat transportation gaps
Jul 24, 2025 12:30 JST
|
|
|
Honda Reveals Details of its Support of the World Athletics Championships Tokyo 25
Jul 24, 2025 12:03 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
